Litcius/Paper detail

Anti-Osteoporotic Effects of Commiphora Myrrha and Its Poly-Saccharide via Osteoclastogenesis Inhibition

Youn‐Hwan Hwang, Ami Lee, Tae Soo Kim, Seon‐A Jang, Hyunil Ha

2021Plants20 citationsDOIOpen Access PDF

Abstract

In traditional oriental medicines, Commiphora myrrha and its resinous exudate (i.e., myrrh) are used as herbal remedies to treat various inflammatory and metabolic disorders. Until now, C. myrrha-derived herbal products are considered useful source for bioactive compounds to manage numerous human diseases. This study investigated the effects of water extract of C. myrrha resin (WCM) and its polysaccharide (WCM-PE) on modulatory effects of osteoclast differentiation and/or ovariectomized-induced bone loss. Oral administration of WCM (200 and 500 mg/kg/day for four weeks) notably decreased trabecular bone loss and lipid accumulation in the bone marrow cavity. WCM and WCM-PE dose-dependently inhibited receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and suppressed RANKL-mediated overexpression of c-Fos and nuclear factor of activated T cells, cytoplasmic 1, thereby downregulating osteoclast-specific gene (Atp6v0d2, DC-STAMP and cathepsin K) expression. Thus, our results suggest that WCM and WCM-PE are promising nutraceutical candidates for the management of osteoporosis in postmenopausal women.

Topics & Concepts

RANKLOsteoclastOvariectomized ratCathepsin KChemistryOsteoporosisPharmacologyNutraceuticalEndocrinologyBone remodelingActivator (genetics)ReceptorInternal medicineCancer researchMedicineBiochemistryHormoneBone Metabolism and DiseasesPharmacological Effects of Medicinal PlantsOsteomyelitis and Bone Disorders Research
Anti-Osteoporotic Effects of Commiphora Myrrha and Its Poly-Saccharide via Osteoclastogenesis Inhibition | Litcius